TY - JOUR
T1 - Treatment of rheumatoid arthritis in patients with concomitant chronic hepatitis C infection
AU - Joseph, Amy M.
PY - 2012/2
Y1 - 2012/2
N2 - Hepatitis C virus (HCV) infection is present in 1.8% of the general US population and its prevalence worldwide is estimated at 2–3%. HCV infected patients with concomitant rheumatoid arthritis (RA) pose a particular challenge to the rheumatologist because of the risks of treatment with disease-modifying medications in patients with chronic liver infection. In this paper the difficulties of diagnosing RA in HCV patients and the safety of RA treatment in patients with both conditions are discussed.
AB - Hepatitis C virus (HCV) infection is present in 1.8% of the general US population and its prevalence worldwide is estimated at 2–3%. HCV infected patients with concomitant rheumatoid arthritis (RA) pose a particular challenge to the rheumatologist because of the risks of treatment with disease-modifying medications in patients with chronic liver infection. In this paper the difficulties of diagnosing RA in HCV patients and the safety of RA treatment in patients with both conditions are discussed.
KW - biological-response modifiers
KW - disease-modifying antirheumatic drugs
KW - hepatitis C
KW - rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=84857462075&partnerID=8YFLogxK
U2 - 10.1177/1759720X11424459
DO - 10.1177/1759720X11424459
M3 - Article
C2 - 22870493
AN - SCOPUS:84857462075
SN - 1759-720X
VL - 4
SP - 35
EP - 40
JO - Therapeutic Advances in Musculoskeletal Disease
JF - Therapeutic Advances in Musculoskeletal Disease
IS - 1
ER -